Connection

Michael Gold to Stroke Volume

Back to Details
This is a "connection" page, showing publications Michael Gold has written about Stroke Volume.
Michael Gold
Connection Strength
2.391
Stroke Volume
  1. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2021 01 05; 143(1):7-17.
    View in: PubMed
    Score: 0.579
  2. Enhanced detection of arrhythmia vulnerability using T wave alternans, left ventricular ejection fraction, and programmed ventricular stimulation: a prospective study in subjects with chronic ischemic heart disease. J Cardiovasc Electrophysiol. 2004 Feb; 15(2):170-6.
    View in: PubMed
    Score: 0.182
  3. Association of left ventricular remodeling with cardiac resynchronization therapy outcomes. Heart Rhythm. 2023 02; 20(2):173-180.
    View in: PubMed
    Score: 0.167
  4. Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results. Heart Rhythm. 2019 11; 16(11):1636-1644.
    View in: PubMed
    Score: 0.131
  5. Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial. J Am Coll Cardiol. 2016 07 12; 68(2):149-58.
    View in: PubMed
    Score: 0.106
  6. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). J Am Heart Assoc. 2015 Sep 11; 4(9):e002054.
    View in: PubMed
    Score: 0.102
  7. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm. 2015 Mar; 12(3):524-530.
    View in: PubMed
    Score: 0.096
  8. Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure. Circ Heart Fail. 2013 Nov; 6(6):1180-9.
    View in: PubMed
    Score: 0.088
  9. The effect of left ventricular electrical delay on AV optimization for cardiac resynchronization therapy. Heart Rhythm. 2013 Jul; 10(7):988-93.
    View in: PubMed
    Score: 0.085
  10. Comparison of fixed tilt and tuned defibrillation waveforms: the PROMISE study. J Cardiovasc Electrophysiol. 2013 Mar; 24(3):323-7.
    View in: PubMed
    Score: 0.084
  11. Risk stratification of ventricular arrhythmias in patients with systolic heart failure. Curr Opin Cardiol. 2010 May; 25(3):268-75.
    View in: PubMed
    Score: 0.070
  12. Use of traditional and biventricular implantable cardiac devices for primary and secondary prevention of sudden death. Cardiol Clin. 2008 Aug; 26(3):419-31, vi-vii.
    View in: PubMed
    Score: 0.062
  13. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007 Sep 18; 50(12):1150-7.
    View in: PubMed
    Score: 0.058
  14. Myocardial contractile reserve as a predictor of cardiac resynchronization therapy response. Heart Rhythm. 2006 Apr; 3(4):414-5.
    View in: PubMed
    Score: 0.052
  15. Long-term outcomes in nonprogressors to cardiac resynchronization therapy. Heart Rhythm. 2023 02; 20(2):165-170.
    View in: PubMed
    Score: 0.042
  16. Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy. J Am Coll Cardiol. 2022 09 27; 80(13):1205-1216.
    View in: PubMed
    Score: 0.041
  17. Influence of QRS duration on the prognostic value of T wave alternans. J Cardiovasc Electrophysiol. 2002 Aug; 13(8):770-5.
    View in: PubMed
    Score: 0.041
  18. Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 2001 Nov; 12(11):1247-53.
    View in: PubMed
    Score: 0.039
  19. Future research prioritization in cardiac resynchronization therapy. Am Heart J. 2020 05; 223:48-58.
    View in: PubMed
    Score: 0.035
  20. The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. Eur J Heart Fail. 2018 04; 20(4):780-791.
    View in: PubMed
    Score: 0.030
  21. Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac?Resynchronization: Results From the REVERSE Trial. JACC Heart Fail. 2017 03; 5(3):169-178.
    View in: PubMed
    Score: 0.028
  22. Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. Heart Rhythm. 2017 03; 14(3):367-375.
    View in: PubMed
    Score: 0.028
  23. Electrophysiologic effects and predictors of success of combination therapy with class Ia and Ib antiarrhythmic drugs for sustained ventricular arrhythmias. Am J Cardiol. 1996 Jul 01; 78(1):47-50.
    View in: PubMed
    Score: 0.027
  24. Dual-chamber pacing with a short atrioventricular delay in congestive heart failure: a randomized study. J Am Coll Cardiol. 1995 Oct; 26(4):967-73.
    View in: PubMed
    Score: 0.025
  25. Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. Eur Heart J. 2015 Nov 01; 36(41):2780-9.
    View in: PubMed
    Score: 0.025
  26. Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). J Card Fail. 2015 Jun; 21(6):479-88.
    View in: PubMed
    Score: 0.025
  27. The Post-Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale. J Card Fail. 2015 Jul; 21(7):601-7.
    View in: PubMed
    Score: 0.025
  28. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013 Dec; 34(46):3547-56.
    View in: PubMed
    Score: 0.022
  29. Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: insights from the SMART-AV multicenter trial. Heart Rhythm. 2012 May; 9(5):736-41.
    View in: PubMed
    Score: 0.020
  30. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011 Mar 15; 123(10):1061-72.
    View in: PubMed
    Score: 0.019
  31. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 Dec 21; 122(25):2660-8.
    View in: PubMed
    Score: 0.018
  32. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009 Nov 10; 120(19):1858-65.
    View in: PubMed
    Score: 0.017
  33. Baseline characteristics of patients randomized in The Resynchronization Reverses Remodeling In Systolic Left Ventricular Dysfunction (REVERSE) study. Congest Heart Fail. 2008 Mar-Apr; 14(2):66-74.
    View in: PubMed
    Score: 0.015
  34. Performance of a new steroid-eluting coronary sinus lead designed for left ventricular pacing. Pacing Clin Electrophysiol. 2000 Nov; 23(11 Pt 2):1741-3.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.